Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leronlimab for Prolonged COVID-19 Symptoms
NCT04678830Phase 2Completed
- Sponsor
- CytoDyn Inc.
- Start
- Mar 2021
- Primary completion
- Jun 2021
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in post acute COVID-19 syndrome comparing Placebo with 700mg Leronlimab (2 arms). Primary endpoint: Changes From Baseline in Daily COVID-19-related Symptom Severity Score at Day 56. Started Mar 2021; status: completed.
02
Drugs
leronlimab
03
Conditions
post acute COVID-19 syndrome
Beyond the preview
Go deeper on NCT04678830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04678830.